Vyzulta (latanoprostene bunod) / Bausch Health, Nicox - LARVOL DELTA

SOCIODEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF LATANOPROSTENE BUNOD INITIATORS AMONG MEDICARE FEE-FOR-SERVICE PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION (ISPOR 2026) - "In this large real-world population, LBN was utilized across a range of OAG severity stages and most commonly observed among patients with baseline IOP ≤21 mmHg. This utilization pattern supports the consideration of LBN as an early therapeutic option for patients requiring effective IOP reduction, including those with normotensive glaucoma."

Clinical • Medicare • Reimbursement • US reimbursement • Cardiovascular • Glaucoma • Ophthalmology

Investigation of the effect of latanoprostene bunod and latanoprost on peripapillary optical coherence tomography angiography. (PubMed, J Fr Ophtalmol) - "In conclusion, LBN administered once a day increased VD in peripapillary OCTA. LP had no effect on VD. Future studies should be aimed at determining whether this effect of LBN is NO induced or due to higher IOP reduction."

Clinical • Journal • Glaucoma • Ophthalmology

Different intraocular pressure-lowering effects of latanoprostene bunod across glaucoma subtypes: a 12-month real-world clinical study. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "LBN demonstrated differential IOP-lowering effects across glaucoma subtypes, with a notably enhanced effect on PXFG. This superior efficacy in PXFG, likely due to LBN's dual mechanism overcoming pseudoexfoliative outflow resistance, suggests that switching from latanoprost may help delay the need for surgical intervention in this challenging patient population."

Journal • Real-world evidence • Glaucoma • Hypotension • Ophthalmology

Angina Pectoris Following Latanoprostene Bunod 0.024% Administration: A Case Report. (PubMed, Cureus) - "Although prostaglandin analogs such as latanoprostene bunod are primarily believed to exert localized ocular effects, they may cause systemic reactions through mechanisms including vasoconstriction and nociceptor sensitization-particularly in susceptible individuals. This case underscores the importance of clinical vigilance for atypical systemic symptoms following initiation of topical glaucoma medications and supports the need for further investigation into their cardiovascular safety profile."

Journal • Cardiovascular • Gastroenterology • Glaucoma • Ophthalmology • Pain

The effect of latanoprostene bunod on retinal vessel density in patients with primary open-angle glaucoma. (PubMed, Eur J Ophthalmol) - "These vascular benefits likely result from nitric oxide (NO)-mediated microcirculatory improvements. Larger, long-term multicenter studies are needed to explore LBN's sustained vascular effects in glaucoma management."

Journal • Glaucoma • Ophthalmology

Evaluation of corneal and anterior segment alterations following short-term use of topical latanoprostene bunod. (PubMed, Int Ophthalmol) - "Short-term use of latanoprostene bunod reduced corneal densitometry values, suggesting improved corneal transparency without significantly affecting corneal thickness, endothelial cell characteristics, or anterior segment parameters. Further long-term studies with larger sample sizes are needed to evaluate its prolonged effects on corneal health."

Journal • Glaucoma • Ophthalmology

Gland Pharma ANDA used in Glaucoma treatment gets USFDA approval (CNBC-TV18) - "Gland Pharma on Wednesday, April 30, said it has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for latanoprostene bunod ophthalmic solution, 0.024%. The product is bioequivalent and therapeutically equivalent to the reference listing drug VYZULTA Opthalmic solution, 0.024% of Bausch and Lomb, Inc....As per the IQVIA, the product had US sales of around $171 million for the 12 months ending February 2025."

ANDA • Sales • Glaucoma • Ophthalmology

Latanoprostene Bunod 0.024% Early Experience Program (LEEP): A Canadian Initiative for Open-Angle Glaucoma and Ocular Hypertension. (PubMed, Ophthalmol Ther) - "This initial Canadian clinical experience of LBN in diverse patient and physician populations reflected its use in a real-world context, and demonstrated a significant IOP-lowering effect with LBN across patient groups seen in routine practice. Patient and physician satisfaction scores were high and in notable agreement."

Journal • Cardiovascular • Glaucoma • Ophthalmology

Drugs for open-angle glaucoma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Glaucoma • Ophthalmology

Corrigendum: Latanoprostene bunod: the first nitric oxide-donating antiglaucoma medication. (PubMed, Med Gas Res) - No abstract available

Journal • Glaucoma • Ophthalmology

Real-world impact of latanoprostene bunod ophthalmic solution 0.024% in glaucoma therapy: a narrative review. (PubMed, Front Ophthalmol (Lausanne)) - "LBN was generally well tolerated in real-world studies; the most common adverse events were consistent with the known safety profile of LBN. Data from real-world studies provide important insights regarding the potential effectiveness and tolerability of LBN in the clinical setting and suggest that LBN is well tolerated and associated with significant, clinically meaningful, and durable reductions in IOP."

Journal • Real-world evidence • Review • Cardiovascular • Glaucoma • Ophthalmology

Impact on intraocular pressure after switching to Latanoprostene Bunod in patients with glaucoma in real-world clinical practice (ARVO 2025) - "These large-scale real-world study findings are consistent with those observed in smaller observational studies and clinical trials, confirming LBN effectiveness in real-world clinical practice Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Real-world • Real-world evidence • Glaucoma • Ophthalmology

Latanoprostene bunod: the first nitric oxide-donating antiglaucoma medication. (PubMed, Med Gas Res) - "Latanoprostene bunod has demonstrated strong efficacy and a favorable safety profile in both clinical trials and real-world studies. Given the promising results of latanoprostene bunod and advancements in drug delivery, topical fixed-combination and sustained-release formulations containing latanoprostene bunod and other agents targeting different intraocular pressure-lowering mechanisms may become available in the future."

Journal • Review • Cardiovascular • Glaucoma • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain

Effects of 0.024% latanoprostene bunod on intraocular pressure and pupil diameter in normal cats and cats with congenital glaucoma. (PubMed, Vet Ophthalmol) - "Transient IOP reduction was observed after topical administration of LAT and LBN in FCG cats; and mean IOP difference was statistically significantly greater in LBN-treated eyes. However, the apparent enhanced hypotensive effect of LBN is not clinically significant."

Journal • Glaucoma • Ophthalmology

The Effect of Latanoprostene Bunod 0.024% on Optical Coherence Tomography Angiography in Newly Diagnosed Open Angle Glaucoma. (PubMed, J Glaucoma) - "In conclusion, treatment with LBN ophthalmic solution 0.024% reduced IOP by an average of 29.9% and 31.8% in patients with POAG and PXG, respectively, and improved VD in different quadrants in all slabs. Therefore, the importance of LBN in the treatment of glaucoma is likely to be that it increases macular microcirculation, possibly via NO, independent of its IOP-reducing effect."

Journal • Glaucoma • Ophthalmology

Reduction in IOP After Switching to Latanoprostene Bunod in Glaucoma Patients in Real-World Clinical Practice (AAO 2024) - "IOP reductions were statistically significant. Conclusion Overall, 33%-46% patients had an IOP reduction of ≥20% after switching to LBN in real-world clinical practice, supporting the effectiveness of LBN therapy."

Clinical • Real-world • Real-world evidence • Glaucoma • Ophthalmology

One-year experience with latanoprostene bunod ophthalmic solution 0.024% in clinical practice: A retrospective observational study. (PubMed, PLoS One) - "Although high intolerable adverse effects including conjunctival hyperemia and eye irritation happened in the first month, remaining sixty percent of patients exhibited statistically significant additional IOP reductions in the replacement of other PGAs during 12 months of clinical use of LBN 0.024%."

Journal • Observational data • Retrospective data • Glaucoma • Ophthalmology

Effect Of Latanoprostene Bunod Ophthalmic Solution On Peripapillary And Macular Density (ESCRS 2024) - No abstract available

Ophthalmology

The comparative effectiveness of latanoprostene and latanoprost in lowering IOP in young guinea pigs, a common myopia model. (ARVO 2024) - "The IOPs (iCare tonometer), cycloplegic refractions (1% cyclopentolate; spherical equivalent refractive errors, SERs), and axial lengths (ALs; Lenstar optical biometer (Haag-Streit) measurements were collected before treatment initiation and weekly thereafter, all at approximately same time of day. The observed reductions in IOP in young guinea pigs treated with both latanoprostene and latanoprost, as opposed to artificial tears, and the slightly greater effect of the former support the further investigation of latanoprostene, specifically its ability to slow progression in a guinea pig myopia model. Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details.: Myopia, commonly known as near-sightedness, manifests as a discrepancy between the eye's refractive power and its axial length, culminating in the..."

HEOR • Glaucoma • Ophthalmology

Intraocular Pressure Reduction Treatment through a Sustained-Release System Loaded with LBN in a Novel Nanoscale Zinc/Iron Mixed-Metal MOF-74 (ARVO 2024) - "We designed Zinc/Iron Mixed-Metal MOF-74 to load the nitric oxide analog Latanoprostene Bunod (LBN), a prostaglandin F2α analog to explore a safe and effective nano-material for delivering LBN with sustained release... The newly developed nano-material represents a promising avenue for reducing intraocular pressure in glaucoma treatment. Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details.: We have developed a nano-material that carries the intraocular pressure-lowering drug LBN."

Glaucoma • Ophthalmology

A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension (clinicaltrials.gov) - P4 | N=0 | Withdrawn | Sponsor: Bausch & Lomb Incorporated | N=34 ➔ 0 | Recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Cardiovascular • Glaucoma • Ocular Inflammation • Ophthalmology

Latanoprostene Bunod 0.024% in Patients with Open-Angle Glaucoma Switched from Prior Pharmacotherapy: A Retrospective Chart Review. (PubMed, Clin Ophthalmol) - "Of 14 ocular AEs, 3 were recorded as such (mild in severity, considered unrelated to treatment), and 11 were identified through review of interval ocular histories (no severity/relatedness information); none led to discontinuation. In this short-term retrospective chart review of mild-to-moderate OAG/OHT, switching prior IOP-lowering therapy to LBN produced an additional ~25% IOP reduction and appeared to be well tolerated."

Journal • Retrospective data • Review • Cardiovascular • Glaucoma • Ophthalmology

NON-INVASIVE EVALUATION OF MEIBOMIAN GLAND MORPHOLOGY AND TEAR FILM AND ANTERIOR SEGMENT PARAMETERS IN TOPICAL LATANOPROST AND LATANOPROSTENE BUNOD USERS FOR OPEN-ANGLE GLAUCOMA MEDICATION (ESCRS-WM 2024) - No abstract available

Glaucoma • Ophthalmology

Ocular Surface Evaluation after Switch from Latanoprost 0.005% to Latanoprostene Bunod 0.024. (PubMed, J Curr Glaucoma Pract) - "Ocular Surface Evaluation after Switch from Latanoprost 0.005% to Latanoprostene Bunod 0.024%. J Curr Glaucoma Pract 2023;17(4):205-209."

Journal • Glaucoma • Ophthalmology

Currently available prostanoids for the treatment of glaucoma and ocular hypertension: A review. (PubMed, Curr Opin Pharmacol) - "Emergent PGAs, such as latanoprostene bunod, fixed-dose netarsudil combined with latanoprost, and omidenepag Isopropyl, offer enhanced or non-inferior IOP reduction. The bimatoprost implant introduces a novel administration method with effective IOP reduction. These developments underscore ongoing progress in PGA-focused ophthalmological research. This article offers a comprehensive review of available prostanoid analogs and explores new developments."

Journal • Review • Cardiovascular • Glaucoma • Ophthalmology